enGene Holdings (ENGN) AI Stock Analysis

• Market Cap: $262.53M
• Dividend Yield: N/A
• Average Volume (3M): 61.21K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.31
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 57
• Sector: Real Estate
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -1.52
• Shares Outstanding: 50,977,560
• 10 Day Avg. Volume: 30,279
• 30 Day Avg. Volume: 61,214
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $21.57
• Price Target Upside: 318.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

enGene Holdings struggles with severe financial difficulties, underlined by zero revenue and consistent losses. The technical analysis suggests bearish momentum. The valuation is poor due to negative earnings and lack of dividends. These factors contribute to a low overall score, indicating significant risk and challenges for potential investors.

Positive Factors

Clinical Trials

The company expanded the number of trial sites in Europe and Asia.

Financial Position

ENGN ended 1Q25 with $273M in cash/marketable securities and reiterated runway guidance into 2027.

Negative Factors

Stock Performance

Investor sentiment has been influenced by cross-trial comparisons to more advanced programs—likely contributing to enGene’s stock trading near the lower end of its 52-week range.

enGene Holdings Business Overview & Revenue Model

Company Description

enGene Holdings (ENGN) is a biotechnology company specializing in the development of innovative gene therapies. The company's core focus is on creating advanced therapeutics for the treatment of chronic diseases by utilizing its proprietary non-viral gene delivery platform. enGene Holdings aims to address unmet medical needs in sectors such as immunology and oncology by offering transformative solutions that enhance patient outcomes.

How the Company Makes Money

enGene Holdings makes money primarily through the development and commercialization of its gene therapy products. The company's revenue model includes licensing its proprietary technology to pharmaceutical partners, collaborating with research institutions for joint product development, and directly selling its therapeutic products upon regulatory approval. Key revenue streams include milestone payments and royalties from partnerships, as well as potential sales from its own product pipeline. Significant partnerships with established pharmaceutical companies enhance its market reach and contribute to its earnings by accelerating the development and commercialization processes.

enGene Holdings Financial Statement Overview

Summary

enGene Holdings shows potential with improvements in net income and a strengthened balance sheet. However, the absence of revenue, ongoing cash burn, and reliance on external financing highlight significant operational and financial challenges typical of biotechnology firms in early development stages. The company must focus on revenue generation and sustainable cash flow management for long-term viability.

Income Statement

enGene Holdings has reported no revenue over the analyzed periods, which is typical for early-stage biotechnology firms focusing on R&D. The company has shown improvement in net income, turning from negative to positive, indicating a potential path towards profitability. However, the lack of revenue generation remains a significant concern.

Balance Sheet

The balance sheet shows a strong equity position with a significant increase in stockholders' equity and total assets. The company has reduced its debt significantly, resulting in a low debt-to-equity ratio. Despite these improvements, the company has a history of negative equity, which poses a risk if not sustained.

Cash Flow

There is a notable increase in financing cash flow, suggesting reliance on external funding. Operating cash flow is consistently negative, indicating cash burn typical for companies at this stage. Free cash flow is also negative, but the growth in financing activities provides temporary liquidity support.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	-175.00K	0.00	0.00
	EBIT
62.30M	-26.06M	-19.43M	-15.87M
	EBITDA
62.30M	-94.77M	-19.45M	-15.70M
	Net Income Common Stockholders
55.14M	-99.92M	-24.46M	-23.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
238.33M	81.52M	20.43M	11.02M
	Total Assets
311.17M	86.96M	23.91M	15.03M
	Total Debt
1.85M	9.78M	32.11M	4.16M
	Net Debt
-171.15M	-71.74M	11.68M	-6.86M
	Total Liabilities
38.56M	14.47M	100.52M	68.47M
	Stockholders Equity
272.61M	72.49M	-76.61M	-53.44M
Cash Flow		Free Cash Flow
-49.21M	-25.06M	-17.75M	-16.23M
	Operating Cash Flow
-48.28M	-24.74M	-17.59M	-15.98M
	Investing Cash Flow
-125.95M	-318.00K	-153.00K	-247.00K
	Financing Cash Flow
265.72M	86.15M	27.97M	22.52M

enGene Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Negative. The current price of 5.15 is below the 20-day moving average (MA) of 5.81, below the 50-day MA of 6.56, and below the 200-day MA of 7.57, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 36.91 is Neutral, neither overbought nor oversold. The STOCH value of 31.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENGN.

enGene Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIIB	69 Neutral	$21.03B	12.85	10.36%	―	-1.60%	39.71%
Sector *	61 Neutral	$4.76B	18.86	-2.89%	8.05%	6.45%	-20.33%
EDIT	48 Neutral	$129.44M	―	-98.10%	―	-58.64%	-40.05%
CRSP	46 Neutral	$3.72B	―	-19.20%	―	-89.95%	-123.71%
SGMO	42 Neutral	$206.96M	―	-156.42%	―	-74.04%	48.16%
ENGN	39 Underperform	$262.53M	―	-44.21%	―	―	―
NTLA	39 Underperform	$962.71M	―	-54.00%	―	59.55%	3.09%

enGene Holdings Corporate Events

enGene Holdings Secures $60 Million for Genetic Medicines

enGene Holdings Inc. plans a $60 million private placement of 6.7 million common shares at $8.90 each, aiming to fund the development of its genetic medicines, particularly detalimogene for bladder cancer. This financing, involving investors like Deep Track Capital and OrbiMed, is expected to close on October 29, 2024. The proceeds are anticipated to support enGene’s operations through 2027. With placement agents including Leerink Partners and Piper Sandler, the securities offered are exempt from U.S. registration, aligning with Nasdaq rules.